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ABSTRACT  
Background: Allergy-related diseases are a public health issue but knowledge on 
development and comorbidity among children is scarce. 
Objective: To study the development of eczema, asthma and rhinitis in relation to sex and 
parental allergy, in a population-based cohort, during childhood.  
Methods: At 1, 2, 4, 8, and 12 years parental questionnaires were used to obtain data on 
allergy-related diseases. Complete data for all 5 follow-up occasions were available from 
2,916 children. Odds ratios for the risk of any allergic disease in relation to heredity and sex 
were calculated using generalized estimating equations. 
Results: At 12 years 58% of the children had had eczema, asthma and/or rhinitis at some 
time. Disease turnover was high for all three diseases throughout the study. Comorbidity 
increased with age and at 12 years 7.5% of all the children were affected by at least two 
allergy-related diseases. Parental allergy was associated with increased comorbidity and 
more persistent disease, and increased the risk of having any allergy-related disease 
(adjusted OR 1.76; 95% CI 1.57-1.97) up to 12 years. Male sex was associated with an 
increased risk throughout childhood. Boys and girls did not differ in disease persistence, and 
for comorbidity the differences were minor.  
Conclusions: Allergy-related diseases may affect a majority of children. Eczema, asthma and 
rhinitis develop dynamically throughout childhood and allergic comorbidity is common. 
These findings indicate that allergy-related diseases should neither be seen nor studied as 
isolated entities.  
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INTRODUCTION 
Allergy-related diseases have become a public health issue. In order to improve disease 
management we need to understand the development and comorbidity of eczema, asthma 
and rhinitis. Data indicate that allergic morbidity in childhood, though transient, is of 
importance for allergy-related diseases in adulthood.(1-5) Comorbidity between eczema, 
asthma and rhinitis has mainly been studied in selected or high risk cohorts of children,(6-
12) but such studies show that comorbidity is substantial and associated with persistence 
and severity(13-15).  
However, we still know little about the development and comorbidity of allergy-related 
diseases over time in a general paediatric population.(16) To our knowledge no study has yet 
investigated the dynamics of changes in eczema, asthma and rhinitis combined, from birth 
until adolescence, and related them to sex and parental allergy. The purpose of this 
prospective study was to investigate the development of eczema, asthma and rhinitis from 
birth up to 12 years of age with a particular focus on comorbidity and disease persistence in 
relation to sex and parental allergy in a population-based birth cohort. 
MATERIAL AND METHODS 
Study subjects 
The BAMSE project is a longitudinal population-based cohort in which children were 
included at birth and prospectively followed during childhood. In brief, parents of all children 
born between 1994 and 1996 living in predefined areas of Stockholm County were asked to 
participate.(17) The BAMSE cohort comprised 4,089 infants, corresponding to 75% of the 
eligible subjects. Detailed data on residential characteristics, environmental factors and 
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parental allergy were obtained when the infant was two months old from a baseline 
parental questionnaire.(17) When the child was 1, 2, 4, 8 and 12 years, the parents 
completed questionnaires focusing on symptoms of eczema, asthma and rhinitis during the 
previous 12 months. To prevent symptoms from being counted twice the questions at age 1 
year asked for symptoms up to 1 year of age and at age 2 years for symptoms between 1 and 
2 years of age. Complete data on all health outcomes at every follow-up were available for 
2,916 children (71% of the original cohort). These children were included in the present 
study so that complete analyses of disease onset, persistence and remission could be 
performed.  
 
Definition of background variables  
Previously identified background variables for the development of allergy-related diseases 
were used in the present analyses. With the exception of duration of breastfeeding, which 
was asked for at one year of age, all variables were based on information from the baseline 
questionnaire: 
Parental allergy: mother and/or father with doctor’s diagnosis of asthma and asthma 
medication and/or doctor-diagnosed hay fever in combination with allergy to furred pets 
and/or pollen and/or doctor’s diagnosis of eczema at the time of enrolment.(18)  
Young mother: maternal age ≤ 25 years at birth of the child.(19) 
Low socioeconomic status: both parents blue collar workers according to the Nordic 
standard occupational classification and Swedish socio-economic classification.(20) 
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Tobacco exposure: mother smoked at least one cigarette per day during pregnancy or at the 
time of enrolment.(21) 
Exclusive breastfeeding during the first four months of life: children breastfed without 
exposure to formula or solid foods.(22)  
Definition of allergy-related disease outcomes  
Assessment of current allergy-related diseases was based on the follow-up questionnaires at 
age 1, 2, 4, 8, and 12 years:  
Eczema: dry skin, itchy rashes with age-specific location for two weeks or more, and/or 
doctor’s diagnosis of eczema in the past 12 months.(23) At age four only data on doctor’s 
diagnosis in the past 24 months were available. To obtain 12-month prevalence rates only 
those reporting itchy rashes with age-specific location for two weeks or more, or use of 
topical corticosteroids in the past 12 months in combination with doctor’s diagnosis of 
eczema in the past 24 months were included in the analysis. 
Asthma – at age 1 and 2 years: at least three episodes of wheeze in combination with 
inhaled corticosteroids and/or signs of bronchial hyperreactivity without concurrent upper 
respiratory infection the year before follow-up. (24) Asthma – at age 4, 8, and 12 years: at 
least four episodes of wheeze in the past 12 months or at least one episode of wheeze in 
combination with occasional or regular use of prescribed inhaled corticosteroids.(18)  
Rhinitis – at age 1 and 2 years: prolonged rhinitis symptoms two months or more in the past 
12 months. Rhinitis at age 4, 8, and 12 years: prolonged rhinitis without common cold in the 
past 12 months.(25) 
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Comorbidity: having at least two of the diseases eczema, asthma or rhinitis at the same 
follow-up. 
New cases: onset of an allergy-related disease which had not been present at any previous 
follow-up. 
Total remission: never having a specific allergy related disease again that had been present 
at the previous follow-up. 
Remission and relapse: not having a specific allergy-related disease that had been present at 
the previous follow-up and that will be present at one or more future follow-ups. 
Statistics 
The prevalence of allergy-related disease was assessed during a 12-month period and 
expressed in percent of total number of observations available. 95% confidence intervals 
(95% CI) were calculated and intervals that did not overlap were considered statistically 
significant. χ2-tests were used for dichotomous variables. For evaluation of differences in 
disease persistence between groups, Wilcoxon Rank Sum test was used. The proportion of 
remission between each follow-up was calculated by dividing the number of remitting cases 
by the total number of children who had the disease at that same time point. The mean 
value for onset for each disease was calculated as the mean of the proportions of new cases 
at age 2, 4, 8 and 12 years. The mean value for remission for each disease was calculated as 
the mean of the proportions of remitting cases at age 1, 2, 4 and 8 years. Generalized 
estimated equations (GEEs)(26) with an unstructured correlation matrix were used to assess 
the impact of parental allergy and sex on development of any allergy-related disease over 
time. The model incorporated an interaction between time and exposure to evaluate the 
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effect of exposure over time. All statistical analyses were performed with STATA Statistical 
Software (release 11.1; StataCorp, College Station, Texas, USA). 
 
RESULTS 
Representativeness of the study samples 
There were no differences between children in the study population (n=2,916) and those in 
the study base (n=4,089) with regard to previously identified risk factors for development of 
allergy related diseases (Table S1). This also held true for the prevalence of eczema, asthma 
and rhinitis, although the rates tended to be somewhat lower for those participating at each 
follow-up (Table S2).  
 
Prevalence rates of allergy-related diseases 
Figure 1 shows the 12-month period prevalence rates for eczema, asthma and rhinitis as well 
as of any of these diseases at age 1, 2, 4, 8, and 12. At 12 years of age, 1,695 children (58%) 
had had at least one of these allergy-related diseases at some time. The prevalence of 
eczema peaked between 2 and 4 years of age, whereas rhinitis continued to increase in 
prevalence with increasing age. Between 4 and 12 years the asthma prevalence was rather 
stable. Twenty-two percent (629 of 2,916) of all children had had one disease at one follow 
up only, while 36% (1,066 of 2,916) either had one disease at more than one follow-up, or 
two or more of the diseases eczema, asthma and rhinitis during the study period. Among 
children with parental allergy, 66% (858 of 1,291) had an allergy-related disease before 12 
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years of age, compared to 52% (837 of 1,625) of children with no parental allergy, p<0.001 
(Fig S1). Notably, children with parental allergy, irrespective of age, had significantly higher 
prevalence of all of the allergy-related diseases studied (all p<0.039) with the exception of 
asthma (p=0.200) and rhinitis (p=0.058) at one year of age. After adjustment for known 
confounders the overall impact of having parental allergy on development of any of the 
diseases eczema, asthma and rhinitis up to 12 years was of 1.76 (95% CI, 1.57-1.97). The 
impact of parental allergy on allergy-related disease development tended to increase with 
age of the study subjects, figure 2. Male sex was associated with an increased risk (adjusted 
OR 1.19, 95% CI 1.06-1.33) for development of any allergy-related disease up to 12 years and 
this association was rather stable over time, figure 2. Boys had a lifetime prevalence of any 
allergy related disease of 60% (892 of 1,488) and the corresponding figure for girls was 56% 
(803 of 1,428), p=0.042. This difference was mainly explained by higher prevalence rates of 
asthma and rhinitis among boys. 
 
Disease turnover and persistence 
Disease turnover, evaluated as onset and remission is illustrated in figure 3. The average 
proportion of new cases of the diseases studied at all observation time points was 53% and 
the corresponding proportion for total remission was 44%. The numbers of new cases, 
remitting cases with subsequent relapse and cases in total remission at all ages, are 
presented in table 1. Figure 3 also shows the proportion of children with eczema, asthma or 
rhinitis who had the disease at one, two or three or more follow-up occasions before 12 
years of age. Since eczema often debuts early in life, it appeared more persistent than 
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asthma and rhinitis. However, from 4 to 12 years of age, disease persistence was almost the 
same for eczema, asthma and rhinitis (data not shown). The pattern of onset and remission 
for eczema, asthma and rhinitis was similar among children with and without parental 
allergy, as well as among boys and girls, even though onset of eczema at 2 years was more 
common among girls (data not shown). Children with parental allergy had more persistent 
eczema, asthma and rhinitis than children without parental allergy, all p<0.001. Boys and 
girls did not differ in terms of disease persistence. 
Comorbidity of eczema, asthma and rhinitis 
The overlap between eczema, asthma and rhinitis at the different follow-ups is illustrated in 
figure 4. Comorbidity became more prevalent with age. At least two allergy related diseases 
were found in 1.8% of the children at 1 year of age. At 2, 4, 8, and 12 years the 
corresponding proportions were 2.3%, 5.9%, 5.5%, and 7.5%. Among children who had an 
allergy related disease, allergic comorbidity was more prevalent among those with parental 
allergy. However, differences in comorbidity between boys and girls were minor (Table 2).  
Asthma did not occur in isolation as often as eczema or rhinitis. Thus, asthma was associated 
with eczema and/or rhinitis in 38% at 1 year and in 67% at 12 years. This is to be compared 
with 42% of children with eczema and 33% of children with rhinitis having any additional 
allergy-related disease at age 12. 
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DISCUSSION 
This study of a large unselected population-based birth cohort provides new insights 
regarding the development and comorbidity of allergy-related diseases in children. We 
found that by the age of 12 years, two out of three children with and every second child 
without parental allergy had had eczema, asthma and/or rhinitis. Furthermore, disease 
turnover was substantial with many new and remitting cases throughout the study period. 
Comorbidity increased from 1.8% at 1 year to 7.5% at 12 years in the study population and 
was more prevalent among children with parental allergy. Sex did not seem to influence 
disease persistence. Asthma was more often associated with eczema and/or rhinitis than 
eczema or rhinitis was associated with any of the other allergy-related diseases.  
 
The strengths of this study are the prospective design and the large number of participants 
with complete data up to 12 years of age, which is unique. Moreover, assessment of eczema, 
asthma and rhinitis, on five occasions during the first 12 years of life reduces the risk of recall 
bias. The prevalence rates for eczema and rhinitis in our study agreed well with other 
population-based studies of similar age groups.(13, 27, 28) However, the asthma prevalence 
tended to be lower than that found by others(29-32), which may be explained by our strict 
definition. The overall prevalence rates found in our study are comparable to the Isle of 
Wight birth cohort study, in which 40% of the children had had an allergy-related disease at 
some time before reaching 4 years of age.(16) In our study the corresponding proportion 
was 45%. 
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One concern about our results is whether the prevalence rates might be overestimated. 
Since the BAMSE birth cohort study was designed to investigate allergy-related diseases it is 
possible that families with children who have allergic symptoms would be more prone to 
participate. However, as shown in table 2, loss to follow-up was more common among 
children with allergy-related diseases, a phenomenon also reported by others (33). With this in 
mind, it is noteworthy that more than half of the children in our study had eczema, asthma 
and/or rhinitis before adolescence, even if parental allergy was not present.  
 
Comparison with other studies 
It is well known that prevalence rates of allergy-related diseases differ between boys and 
girls and between families with and without allergic disease. However, reports on the 
influence of sex and parental allergy on allergic comorbidity are scarce. No obvious 
differences between boys and girls could be found in the German MAS study when rhinitis 
and concomitant wheeze were evaluated.(34) In our study, sex did not influence the 
persistence of any of the conditions studied. Disease turnover was only slightly affected by 
sex, with onset of eczema being more common among girls 2 years old. Similarly, the Isle of 
Wight study found no sex differences in disease turnover up to 10 years of age among 
children with eczema. However, from 10 to 18 years remission was more common among 
boys.(28) Onset and remission of asthma did not differ between boys and girls in our study, 
in congruence with some, but not all previous reports. In a recent study of remission and 
disease persistence among children 5-12 years with asthma, no influence of sex could be 
demonstrated.(35) However, in a selected cohort of children with doctor’s diagnosis of 
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asthma before 6 years of age and followed up to 12 years, asthma was more persistent in 
boys than in girls.(36) Furthermore, it has recently been shown that sex differences in 
prevalence rates of asthma among teenagers may partly be explained by higher remission of 
asthma among boys.(37) These apparently contradictory results might be explained by 
differences in study design and selection of subjects, but also by age differences among the 
children in the different studies. This underlines the need for population-based cohorts 
followed over a long time. 
Asthma seems to present as a single disease in less than half of the cases after 4 years of age 
and a probable explanation could be that the asthma definition we used does not include 
milder cases. However, another study showed that 56% of 5-year-old children with wheeze 
had concomitant eczema and/or rhinoconjunctivitis.(38) This knowledge may be of 
importance when studying phenotypes of allergy-related diseases in relation to early life 
events. The large number of new and remitting cases at all ages found in our study raises the 
question of when an outcome should be evaluated – and over how long a time period – in 
studies addressing risk factors for disease development in childhood.  
 
Conclusions  
We found that allergy-related diseases affect a majority of the paediatric population during 
the first 12 years of life and that the development of eczema, asthma and rhinitis is a 
dynamic process: both new cases and remission are common throughout childhood. These 
findings call for further research to identify phenotypes on the basis of comorbidity and 
disease development that are associated with subsequent disease.  
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Tables  
 
Table S1  Distribution of risk factors for allergy-related diseases in the study population 
compared to the study base 
 
  Variable* Study base   Study population 
Data collected at enrolment  N=4,089 (100%)   n=2,916 (71.3%) 
    n % 95% CI   n % 95% CI 
 
Sex 
       
     Male 2065/4089 50.5 49.0–52.0   1488/2916 51.0 49.2–52.8 
 
Parental allergy** 
       
     any or both 1746/4045 43.2 41.6–44.7   1291/2916 44.3 42.5–46.1 
 
Maternal age 
       
     < 25 years 319/4088 7.8 7.0–8.6   196/2915 6.7 5.8–7.6 
 
Socioeconomic status 
       
     blue collar workers 695/4018 17.3 16.1–18.5   431/2882 15.0 13.7–16.3 
 
Maternal tobacco smoking*** 
       
     Yes 563/4086 13.8 12.7–14.8   346/2916 11.9 10.7–13.0 
         
Data collected at 1 year n=3,925 (96%)   n=2,916 (71.3%) 
    n % 95% CI   n % 95% CI 
 
Breastfeeding exclusive ≥4 months 
      
     No 803/3919 20.5 19.2–21.8   543/2912 18.7 17.2–20.1 
         
*Internal missing 0–1.7%  
       
**Doctor’s diagnosis of asthma and/or hay fever in combination with allergy to furred pets and/or 
   pollen and/or doctor’s diagnosis of eczema at enrolment 
  
***Mother smoked at least one cigarette per day during pregnancy and at the time of enrolment 
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Table S2  Twelve-month prevalence rates of allergy-related diseases in the study population 
compared to the study base  
                  
Variable 
study base 
  
study population 
            
1 year n %  95% CI    n % 95% CI  
Eczema 594/3923 15.1 14.0–16.3   440/2916 15.1 13.8–16.4 
Asthma 151/3924 3.9 3.2–4.5   101/2916 3.5 2.8–4.1 
Rhinitis 145/3920 3.7 3.1–4.3   103/2916 3.5 3.1–4.3 
                
2 years n %  95% CI    n % 95% CI  
Eczema 730/3839 19.0 17.8–20.3   542/2916 18.6 17.2–20.0 
Asthma 219/3835 5.7 5.0–6.4   157/2916 5.4 4.6–6.2 
Rhinitis 154/3840 4.0 3.4–4.6   112/2916 3.8 3.1–4.5 
                
4 years N % 95% CI    n %  95% CI 
Eczema 729/3721 19.6 18.3–20.9   546/2916 18.7 17.3–20.1 
Asthma 260/3704 7.0 6.2–7.8   182/2916 6.2 5.4–7.1 
Rhinitis 413/3685 11.2 10.2–12.2   314/2916 10.8 9.6–11.9 
                
8 years N % 95% CI    n % 95% CI  
Eczema 428/3397 12.6 11.5–13.7   355/2916 12.2 11.0–13.4 
Asthma 215/3397 6.3 5.5–7.1   177/2916 6.1 5.2–6.9 
Rhinitis 462/3409 13.6 12.4–14.7   380/2916 13.0 11.8–14.3 
                
12 years N % 95% CI    n % 95% CI  
Eczema 399/3353 11.9 10.8–13.0   339/2916 11.6 10.5–12.8 
Asthma 221/3339 6.6 5.8–7.5   189/2916 6.5 5.6–7.4 
Rhinitis 693/3337 20.8 19.4–22.1   601/2916 20.6 19.1–22.1 
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Table 1  New and remitting cases from 1 to 12 years for eczema, asthma 
and rhinitis in the BAMSE birth cohort 
        
Eczema        
 all cases new cases total remission remission & relapse 
age (yrs) n n % n % n % 
1 440 440 na 118 26.8 65 14.8 
2 542 285 52.6 164 30.3 65 12.0 
4 546 191 35.0 267 48.9 63 11.5 
8 355 90 25.4 212 59.7 na  
12 339 94 27.7 na    
        
Asthma        
 all cases new cases total remission remission & relapse 
age (yrs) n n % n % n % 
1 101 101 na 34 33.7 13 12.9 
2 157 103 65.6 66 42.0 18 11.5 
4 182 102 56.0 90 49.5 15 8.2 
8 177 87 49.2 97 54.8 na  
12 189 83 43.9 na    
        
Rhinitis        
 all cases new cases total remission remission & relapse 
age (yrs) n n % n % n % 
1 103 103 na 48 46.6 33 32.0 
2 112 90 80.4 60 53.6 32 28.6 
4 314 279 88.9 131 41.2 58 18.5 
8 380 225 59.2 144 37.9 na  
12 601 287 47.8 na    
        
New cases are defined as onset of an allergy-related disease which had not been present 
at any previous observational point. Total remission is defined as never having a specific 
allergy related disease again that had been present at the previous follow-up. Remission 
& relapse is defined as not having a specific allergy-related disease that had been 
present at the previous follow-up and that will be present at one or more future follow-
ups. 
na = not applicable  
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Table 2 Comorbidity* among children 1 to 12 years with allergy-related disease in the 
BAMSE birth cohort according to sex and parental allergy 
        
 parental allergy (n=1,291)  no parental allergy (n=1,625) 
age(yrs) n % 95% CI  n % 95% CI 
1 33/315 10.5 7.1–13.9  20/270 7.4 4.3–10.6 
2 38/395 9.6 6.7–12.5  28/338 8.3 5.3–11.2 
4 115/455 25.3 21.3–29.3  56/398 14.1 10.6–17.5 
8 108/408 26.5 22.2–30.8  48/318 15.1 11.1–19.1 
12 139/484 28.7 24.7–32.8  79/397 19.9 16.0–23.8 
        
 boys (n=1,488)  girls (n=1,428) 
age(yrs) n % 95% CI  n % 95% CI 
1 37/321 11.5 8.0–15.0  16/264 6.1 3.2–9.0 
2 38/399 9.5 6.6–12.4  28/334 8.4 5.4–11.4 
4 110/454 24.2 20.3–28.2  61/399 15.3 11.7–18.8 
8 81/397 20.4 16.4–24.4  75/329 22.8 18.2–27.4 
12 119/470 25.3 21.4–29.3  99/411 24.1 19.9–28.2 
        
*Comorbidity is defined as having two or three of the diseases eczema, asthma and rhinitis at 
the same follow-up. Statistically significant differences are written in bold. 
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Figures
 
Footnote: 
12-month prevalence of eczema, asthma, rhinitis and any symptom at age 1, 2, 4, 8, and 12 
years. Empty bars show the cumulative prevalence at 12 years (n=2,916) 
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Footnote: 
12-month prevalence of eczema, asthma, rhinitis and any symptom at age 1, 2, 4, 8, and 12 
years in children with and without parental allergy. Empty bars show the cumulative 
prevalence at 12 years. 
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Footnote: 
†eczema and/or asthma and/or rhinitis * ORs and 95% CIs were calculated by using GEEs, 
adjusted for the confounders: exclusive breastfeeding <4 months, maternal smoking, low 
socioeconomic status and young mother (< 26 years) n=2.916 
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Figure 3   
Disease turnover and persistence up to 12 years of age in the BAMSE birth cohort 
 
Footnote:  
Turnover indicates the percentage in the population (n=2,916) of new and remitting cases at 
each observation point. New cases were defined as onset of disease which had not been 
present at any previous observation point and remission was defined as not having a disease 
that had been present at the previous observation point. Persistence indicates the 
proportion of children who had a disease at one, two or three or more observation points 
among the children who had ever had the same disease.  
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Figure 4 
Comorbidity of eczema, asthma and rhinitis up to 12 years in the BAMSE birth cohort 
 
Footnote: 
Venn diagrams showing comorbidity between eczema, asthma and rhinitis at age 1, 2, 4, 8, 
and 12 years. 
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